**Project Portfolio**

**Project Name**

**Company Name, City**

*(Please, name all involved legal entities of the company including legal identification number.)*

Member-State

Company logo

**Project period:**

MM.YYYY – MM.YYYY

**Work stream(s): “XXX”, “YYY”, etc.**

*(Please, name all work streams the individual project will address.)*

**Work package(s):**

*(Please, name all work packages the individual project will be involved.)*

Table of Content

[1 Project Outline 4](#_Toc97656122)

[1.1 Company Presentation 4](#_Toc97656123)

[1.2 Objectives of the project in the IPCEI in all workstreams it’s involved 4](#_Toc97656124)

[1.2.1 Executive summary of the project 4](#_Toc97656125)

[1.2.2 Contribution to EU objectives 4](#_Toc97656126)

[1.2.3 Contribution of the individual project to the integrated IPCEI on Health 4](#_Toc97656127)

[1.3 R&D Projects Before IPCEI 5](#_Toc97656128)

[1.4 Technology and Challenges – R&D&I Activities within this project in all work streams it’s involved 5](#_Toc97656129)

[1.4.1 WP 1 : XXXXXXX (have to be repeated for each WP) 5](#_Toc97656130)

[1.4.1.1 Global state of the art 6](#_Toc97656131)

[1.4.1.2 Technical locks that prevent improvements in the field 6](#_Toc97656132)

[1.4.1.3 Objectives and technical challenges in the project 6](#_Toc97656133)

[1.5 First Industrial Deployment (FID) 6](#_Toc97656134)

[1.5.1 Purpose of the FID phase 6](#_Toc97656135)

[1.5.1.1 Description of the investment and ramp up phase 6](#_Toc97656136)

[1.5.1.2 Innovation challenges in the FID phase and links with R&D phase during the ramp up phase 7](#_Toc97656137)

[1.5.2 Technical challenges in the FID phase 7](#_Toc97656138)

[1.5.3 Transition from the FID phase to the mass production / commercialisation phase 7](#_Toc97656139)

[1.5.4 Revenues in the FID phase 7](#_Toc97656140)

[1.6 Contribution to the strategic value chain 8](#_Toc97656141)

[1.6.1 Project’s position in the strategic value chain 8](#_Toc97656142)

[1.6.2 Industrial value chain in the financing MS 8](#_Toc97656143)

[1.6.3 Industrial value chain in Europe 8](#_Toc97656144)

[1.7 Work Plan 8](#_Toc97656145)

[1.8 Investments 8](#_Toc97656146)

[1.8.1 Tools and Equipment 8](#_Toc97656147)

[1.8.2 Construction of Buildings/Laboratory 9](#_Toc97656148)

[2 Budget 11](#_Toc97656149)

[2.1 Eligible Costs 11](#_Toc97656150)

[2.2 Financing plan 11](#_Toc97656151)

[2.3 State Aid 11](#_Toc97656152)

[3 Integration of the project in the IPCEI 13](#_Toc97656153)

[3.1 Contribution of the project to the IPCEI objectives in each relevant Technical Field 13](#_Toc97656154)

[3.1.1 Contribution to the resolution of identified failures 13](#_Toc97656155)

[3.1.2 Contribution to the IPCEI Objectives 13](#_Toc97656156)

[3.1.3 Integration of the project in the IPCEI action plan/programme 13](#_Toc97656157)

[3.1.4 Integration of the project in the IPCEI technological roadmap 13](#_Toc97656158)

[3.2 Complementarity to other individual projects in the IPCEI contributing to the same objectives 13](#_Toc97656159)

[3.2.1 Complementarity intra-TF/intra-WS 14](#_Toc97656160)

[3.2.2 Complementarity with other TF/WS 14](#_Toc97656161)

[3.2.3 Contribution to a global roadmap or programme 14](#_Toc97656162)

[4 Spill-over Effects 16](#_Toc97656163)

[4.1 Spill-over by non-protected results diffusion 16](#_Toc97656164)

[4.2 Spill-over by IP protected results diffusion 16](#_Toc97656165)

[4.2.1 General Intellectual Property principles within the IPCEI 16](#_Toc97656166)

[*4.2.2* Dissemination by IP protected results diffusion 17](#_Toc97656167)

[4.3 Spill-over in FID phases 17](#_Toc97656168)

[4.4 Spill-over through collaboration with indirect participants 18](#_Toc97656169)

[5 Other positive effects on the market 19](#_Toc97656170)

[5.1 Increasing the level of R&D and innovations in Europe 19](#_Toc97656171)

[5.2 Impact of the Project on Employment and New Investments in Europe 19](#_Toc97656172)

[5.3 Environmental protection and energy and security dependence 19](#_Toc97656173)

[5.4 Health data 19](#_Toc97656174)

[5.5 Market failures affecting the individual project 19](#_Toc97656175)

[5.5.1 Coordination challenges 20](#_Toc97656176)

[5.5.1.1 Coordination failures between companies and research organizations 20](#_Toc97656177)

[5.5.1.2 Coordination failures between European research organizations themselves 20](#_Toc97656178)

[5.5.1.3 Coordination failures between SMEs and industry leaders 20](#_Toc97656179)

[5.5.1.4 Coordination failures between European clusters 20](#_Toc97656180)

[5.5.1.5 Coordination failures of a very large-scale R&D project 20](#_Toc97656181)

[5.5.1.6 Coordination failures associated with contractual incompleteness 20](#_Toc97656182)

[5.6 Imperfect and asymmetric information 20](#_Toc97656183)

[5.6.1 Risks affecting the project 20](#_Toc97656184)

[5.6.2 Other market failures 21](#_Toc97656185)

[5.7 Adequacy of the state aid instrument 21](#_Toc97656186)

[6 Incentive effect 23](#_Toc97656187)

[6.1 Absence of similar projects 23](#_Toc97656188)

[6.2 Start date of the project 23](#_Toc97656189)

[6.3 Counterfactual scenario 23](#_Toc97656190)

[7 Elaboration on Terms of the Funding Gap Questionnaire 25](#_Toc97656191)

[7.1 Main hypothesis of the business plan 25](#_Toc97656192)

[7.2 Necessity of state aid 26](#_Toc97656193)

[7.3 Proportionality of state aid 26](#_Toc97656194)

[7.3.1 Aid beneficiary’s hurdle rate 26](#_Toc97656195)

[7.3.2 Project’s funding gap 27](#_Toc97656196)

[7.3.3 Costs and state aid 27](#_Toc97656197)

[7.3.4 State aid cumulation 27](#_Toc97656198)

[7.3.5 Open selection proceeding 27](#_Toc97656199)

[7.4 Claw-Back Mechanism 27](#_Toc97656200)

[8 Limitation of distortion of competition and trade 28](#_Toc97656201)

[8.1 Market affected by the State aid 28](#_Toc97656202)

[8.1.1 Current Industry Sector 28](#_Toc97656203)

[8.1.2 Estimation of the market situation 28](#_Toc97656204)

[8.2 Limiting distortion of dynamic incentives 28](#_Toc97656205)

[8.3 Failure to maintain an inefficient market structure 28](#_Toc97656206)

[8.4 No effect on location activities 28](#_Toc97656207)

[9 Annex to the Portfolio 29](#_Toc97656208)

1. Project Outline
	1. Company Presentation

***Max 1,5 pages***

*Please give a brief description of your company and type of company mentioning:*

* *The structure of the company (belonging to a group or independent structure)*
* *Number of employees (if relevant for the group)*
* *Turnover of the last year*
* *Mains activities*
* *Position in the value chain of the company and product portfolio*
* *Activities that are developed in the IPCEI*

INSERT YOUR TEXT HERE.

* 1. Objectives of the project in the IPCEI in all workstreams it’s involved

**Max 5 pages including photos and figure**

*Please give a brief description of the overall objectives of activities in all work streams (WS) the project is involved, linking objectives between WS.*

* + 1. Executive summary of the project

*Please shortly present the project. One page maximum. Please focus on a global view:*

* *Scope of the project : R&D and FID (list of WP linked to eligible costs (part 2 and Funding gap questionnaire))*
* *R&D and FID objectives : Explain general innovative aspect of the project*
* *Duration of the project*
* *Location of the project*

INSERT YOUR TEXT HERE.

* + 1. Contribution to EU objectives

*Indicate here to which general EU objectives the project will contribute in a concrete and measurable manner (see paragraphs 4 and 14 of the revised communication of the Commission on the IPCEI).*

INSERT YOUR TEXT HERE.

* + 1. Contribution of the individual project to the integrated IPCEI on Health

*Include in this section the following information:*

* *Summary description of how the individual project concretely contributes to and significantly adds value for the achievement of the goals of each work stream (WS) it’s involved and within each WS, of each IPCEI work package (WP) it is participating in (please use the actual names of the structural elements of the IPCEI as adopted in its Chapeau)*
* *Summary description of the achievement of the European objective pursued by the IPCEI on Health, and how it is based on the same coherent systemic approach and included in the same roadmap and program.*

INSERT YOUR TEXT HERE AND FILL IN THE TABLE BELOW.

|  |  |  |  |
| --- | --- | --- | --- |
| **Individual project objectives** | **IPCEI related objectives** | **IPCEI WS, WP and associated deliverable** | **Involved Participants** |
| **Direct/Associated** | **Indirect** |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

Table 1: overview oft he project's integration into the IPCEI on Health

* 1. R&D Projects Before IPCEI

**Max 3 pages**

*Description of the R&D-activities which were necessary for this individual IPCEI project and that were carried out before start of the project (background).*

*Explain in this section the concrete link with previous R&D activities, including project scope, duration and context (EU project, national project, grantor, cooperation project etc.) as well as concrete inputs for this IPCEI project.*

*If the company do not have no prior R&D&I project(s), please explain why by using and completing the following sentence:No prior R&D&I activities related to the conduct of the individual project were carried out by COMPANY NAME because [COMPLETE].*

INSERT YOUR TEXT HERE OR USE THE TABLE BELOW.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Previous R&D Project** | **Context** | **Period** | **Project scope** | **Contribution to the current IPCEI** |
| *Name of project, cost and if applicable the level of reveived support* | *e.g. National, EU, cooperation project* | *Start, Duration, End* | *indicate project scope, partners names,…* | *give the concrete inputs needed for the project* |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

Table 2: R&D projects before this IPCEI on Health

* 1. Technology and Challenges – R&D&I Activities within this project in all work streams it’s involved

**No more than 50 pages**

*For each WS (and WP) that are linked to the eligible costs (part 2 and funding gap questionnaire) describe the state of art, the technical locks, the objective and the technical challenge to solve the technical locks.*

* + 1. WP 1 : XXXXXXX (have to be repeated for each WP)
			1. Global state of the art

*Give a view of the global and European state of the art for the technology or product that this project intends to develop (and/or first industrially deploy). Please give a clear insight of the state of the art related to what will be undertaken in your project, giving measurable elements to assess the current state of the art considered as a reference.*

*Give (if applicable) information about the expectations of the market or the ecosystem (if needed related to general EU objectives – such as Green Deal) that require to go beyond the current state of the art.*

INSERT YOUR TEXT HERE.

* + - 1. Technical locks that prevent improvements in the field

*With respect to the previously presented state of the art, explain what the limits of the current technologies are. Indicate which technical locks limit innovation in the domain.*

INSERT YOUR TEXT HERE.

* + - 1. Objectives and technical challenges in the project

*Based on the previously explained technical locks, indicate which challenges the company wants to overcome and how. Use a work-packages-based structure within this individual project that enable to quantify the effort in terms of R&D, investment.*

*This WP structure (e.g. in form of a Gantt-Chart) shall be presented in a coherent manner with the rest of the document.*

INSERT YOUR TEXT HERE.

* 1. First Industrial Deployment (FID)

***No more than 10 pages***

*For each WP describe the FID investment and linked Opex insisting on the description of beginning of FID (after R&D&I phases) and the end of FID (before mass production). Cf. FID definition in Guidelines.*

*Provide a clear timeline, at the beginning of the section, of the duration of the RDI and FID phases, linking them to the relevant WP. Should the RDI and FID phases overlap for some of the work packages, please provide explanations and justifications (e.g. how the FID will incorporate the technologies developed during the RDI phase if FID starts shortly after the launch of the RDI).*

* + 1. Purpose of the FID phase
			1. Description of the investment and ramp up phase

*For each WP linked with eligible costs (part 2 and funding gap questionnaire) describe the FID investment and linked Opex insisting on the description of beginning of FID (after R&D phases) and the end of FID (before mass production).*

INSERT YOUR TEXT HERE.

* + - 1. Innovation challenges in the FID phase and links with R&D phase during the ramp up phase

*Explain how the ramp up is increasing and the process or product innovation that are elaborated or tested during this phase (responding to IPCEI’s definition on FID) and how it’ll tested with some of users on some sample or product that are not yet compliant with KPIs presented on 1.5.3 hereafter*

INSERT YOUR TEXT HERE.

* + 1. Technical challenges in the FID phase

*Please demonstrate in a detailed and exhaustive manner whether the claimed first industrial deployment in your project:*

1. *itself contains an important R&D&I component which constitutes an integral and necessary element for the successful implementation of the project;*
2. *allows for the development of a new product or service with high research and innovation content or the deployment of a fundamentally innovative production process;*
3. *does not cover regular upgrades without an innovative dimension of existing facilities and the development of newer versions of existing products;*
4. *involves the upscaling of pilot facilities, demonstration plants or of the first-in-kind equipment and facilities covering the steps subsequent to the pilot line including the testing phase and bringing batch production to scale;*
5. *does not cover mass production (in view of relevant R&D&I-related performance indicators, which should be quantified and measurable);*
6. *does not cover commercial activities (noting that limited sales, when necessary in the specific sector, related to the testing phase, including sample or feedback or certification sales, are excluded from the notion of “commercial activities”);*
7. *follows on from an R&D&I activity that is also described in this project portfolio (noting that the first industrial deployment does not need to be carried out by the same entity that carried out the R&D&I activity, as long as that entity acquires the rights to use the results from the previous R&D&I activity, and the R&D&I activity and the first industrial deployment are both described in the project).*

INSERT YOUR TEXT HERE.

* + 1. Transition from the FID phase to the mass production / commercialisation phase

*Give quantified and measurable R&D&I-related KPIs to justify the transition (ex: defect rate 10%). Indicate WHEN the transition shall take place. This date must be coherent with the funding gap questionnaire.*

INSERT YOUR TEXT HERE.

* + 1. Revenues in the FID phase

*Which revenues are expected, from which sales which products, when and which users. This data must be coherent with the FGQ.*

INSERT YOUR TEXT HERE.

* 1. Contribution to the strategic value chain
		1. Project’s position in the strategic value chain

*The definition of the value chain can correspond to technological layers/segments or typologies of actors*

INSERT YOUR TEXT HERE.

* + 1. Industrial value chain in the financing MS

INSERT YOUR TEXT HERE.

* + 1. Industrial value chain in Europe

INSERT YOUR TEXT HERE.

* 1. Work Plan

***2 to 5 pages***

*Please describe your work plan in respect to the described work linked with the work streams of the project.*

*Include a Gantt to explain the development of the project over time*

*Indicate here the staff resources that will be assigned to the project. These resources must be consistent with the eligible costs presented in part 2 and in the funding gap questionnaire.*

INSERT YOUR TEXT HERE AND USE THE TABLE BELOW FOR AN OVERVIEW.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| IPCEI WS | IPCEI WP\* | Title of individual WP | Total PM | PM for R&D&I | PM for FID |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
| Total PM |  |  |  |

Table 3: Work stream (WS) / Work Packages (WP) vs. Person Months (PM) \*Indicate the number of IPCEI WP.

* 1. Investments
		1. Tools and Equipment

***1 to 3 pages***

*Please cluster your investment by technology classification. Please provide also a brief and simple description of 1 or 2 sentences to the table about the purpose of the investment. Indicate the depreciation duration applicable to these tools and equipment (coherent with the FGQ).*

*This investments shall reflect the costs of instrument and equipment necessary to the project that are in the funding gap questionnaire (cost of investments) line b) and bb). Please indicate whether equipment are going to be used solely for the sake of the IPCEI project.*

INSERT YOUR TEXT HERE AND FILL OUT THE TABLE BELOW.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| TechnologyClassification | No. of Tools | Examples of Tools | Investment Cost [EUR] | Year\* | WS | WP\*\* | Usage\*\*\*[%] |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| Total |  |  |  |  |  |

\*Investment year

\*\* Indicate the number of IPCEI WP.

\*\*\* Indicate the % of use for the IPCEI Project (100%: fully dedicated to the IPCEI; below >100%: shared with other projects: in this case explain the share and adapt the eligible costs accordingly in the FGQ)

Table 4: Overview of investment in tools and equipment

* + 1. Construction of Buildings/Laboratory

*Please provide a brief and simple description of 1 or 2 sentences to the table about the kind of building/facility and the purpose. Please cluster your investment that are necessary to the project that are in the funding gap questionnaire line c) and cc). Indicate the depreciation duration applicable to these buildings (coherent with the FGQ). Please clarify whether the buildings and laboratories (or any extensions of the company’s premises) are going to be used solely for the sake of the IPCEI project.*

INSERT YOUR TEXT HERE AND FILL OUT THE TABLE BELOW.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Description of facilities | No. of facilities | Purpose | Investment Cost [EUR] | Year\* | WS | WP\*\* | Usage\*\*\*[%] |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| Total |  |  |  |  |  |

\*Investment year

*\*\*Indicate the number of IPCEI WP*

\*\* Indicate the % of use for the IPCEI Project (100%: fully dedicated to the IPCEI; below >100%: shared with other projects: in this case explain the share and adapt the eligible costs accordingly in the FGQ)

Table 5: Overview of investment in buildings or laboratories

1. Budget
	1. Eligible Costs

*Eligible costs only cover costs made for the purpose and the time span of the IPCEI:*

*The following costs should be listed in a disaggregate manner:*

* *Costs for each of the R&D&I activities*
* *Costs for each of the FID activities*
* *And, within the FID costs, the costs of R&D&I carried out in the FID phase should be mentioned; this could give an idea of the overall importance of the R&D&I*
* *The cut-off date of the R&D&I and FID phases should be provided explicitly by each company. This must be coherent with the FGQ.*
* *Eligible costs cover costs up to the end of the FID phase (even if the FID phase goes beyond the national granting period for some companies)*
* *The end result of this step should be one figure: the total amount of eligible costs at the end of the IPCEI, including the FID phase*

*Note: all costs mentioned in the FGQ are considered by the Member States as eligible costs under the IPCEI Communication.*

INSERT YOUR TEXT HERE AND FILL OUT THE TABLE BELOW.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Construction of facilities\**(FGQ: c and cc)* | Investment Costs\**(FGQ: b and bb)* | Personnel Costs*(FGQ: f and ff)* | Subcontract Costs*(FGQ: a and aa)* | Materials, Supplies and Others*(FGQ: d, dd, e, ee, h and hh)* | Total Costs |
| R&D&I |  |  |  |  |  |  |
| FID |  |  |  |  |  |  |

Table 6: Eligible Costs (R&D&I and First Industrial Deployment)[[1]](#footnote-1) [EUR]; \* with respect of the terminal values at the end of first industrial deployment phase in MM.YYYY.

* 1. Financing plan

*On the basis of the project's funding gap questionnaire, specify how the company will contribute to the financing of the project, including through private sources of finance (equity, debt). On the basis of eligible costs, indicate whether other aid has been requested at national, regional or European level.*

INSERT YOUR TEXT HERE.

* 1. State Aid

*Indicate the State aid requirement in nominal terms and discounted terms, as well as the anticipated yearly instalments in the following text:*

Without public funding, a positive NPV would not be met for [Name of the company] project: there is a negative funding gap of XXX k€ with a post-tax WACC of [X] % (see below chapter 7).

The state aide demand from [name of the company] is set as it follows: To compensate for the negative NPV of the project (or to cover the eligible costs if they are < to the funding gap), the maximum required State aid from France is a nominal grant of **XXX k€**. Total eligible costs amount to XXX k€.The State aid intensity would therefore amount to **XX % of eligible costs**. The discounted value (at XX %) of the XXXX k€ nominal grant amounts (based on proportional installments) to XXX k€: it is equal to the Funding gap. At this stage the state aid demand from the company has not been discussed between France and [The Company].

France commits that the maximum State aid amount depreciated at the WACC rate, post-tax, of the company during the financing period won’t exceed the funding gap or the eligible costs (if the amount of eligible costs is < to the funding gap) .

FILL OUT THE TABLE BELOW.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Construction of facilities\**(FGQ: c and cc)* | Invest Costs\**(FGQ: b and bb)* | Personnel*(FGQ: f and ff)* | Subcontracts*(FGQ: a and aa)* | Materials, Supplies and Others*(FGQ: d, dd, e, ee, h and hh)* | State aid instrument | Planned Total State Aid | Gross grant equivalent |
| RDI |  |  |  |  |  |  |  |  |
| FID |  |  |  |  |  |  |  |  |

Table 7: State Aid (R&D&I and First Industrial Deployment) 1 [EUR]. \*depreciations

1. Integration of the project in the IPCEI
	1. Contribution of the project to the IPCEI objectives in each relevant Technical Field

*Description how the individual project concretely contributes to and significantly adds value for the achievement of the goals of each technology field (TF), and within each TF, of each workstream (WS) to which it is participating (please use the actual names of the structural elements of the IPCEI as adopted in its Chapeau), and thus – to the achievement of the European objective pursued by the IPCEI.*

*Show how the project contributes to:*

* *The resolution of identified failures (Causes);*
* *Contributes to identified and specific objectives (goals);*
* *Implements solutions that are part or a general action plan (achievements);*
* *Is a brick in the technological common construction (perspectives);*
	+ 1. Contribution to the resolution of identified failures

*Identify here the failures causes in the chapeau document to which the project will bring a concrete solution.*

INSERT YOUR TEXT HERE.

* + 1. Contribution to the IPCEI Objectives

*Identify and explain which IPCEI objectives in the chapeau document the project will bring a concrete contribution.*

INSERT YOUR TEXT HERE.

* + 1. Integration of the project in the IPCEI action plan/programme

INSERT YOUR TEXT HERE.

* + 1. Integration of the project in the IPCEI technological roadmap

INSERT YOUR TEXT HERE.

* 1. Complementarity to other individual projects in the IPCEI contributing to the same objectives

**Between 5 to 15 pages**

*Please provide specific description how the individual project for which aid is requested is complementary to the other individual projects in the IPCEI, and significantly adds value in contributing to the same objectives:*

* *how,  in concrete terms, the individual project is interlinked with the other individual projects in the same TF and its WSs, and across TFs and WSs;*
* *how it is based on the same coherent systemic approach and included in the same  roadmap and programme (for this IPCEI), contributing thus to the same objectives (of the WS, TF and IPCEI);*
	+ 1. Complementarity intra-TF/intra-WS

*Describe here the complementarity with other projects in the same WS, using concrete terms and demonstrating synergies and complementarities. Please follow the guidance provided above.*

* *Contribution to similar failures compensation actions;*
* *Complementarity of the actions;*
* *Complementary contribution to the technological roadmap;*

INSERT YOUR TEXT HERE.

* + 1. Complementarity with other TF/WS

*Describe here the complementarity with other projects in different TF or WS, using concrete terms and demonstrating synergies and complementarities. Please follow the guidance provided above.*

* *Contribution to similar failures compensation actions;*
* *Complementarity of the actions;*
* *Complementary contribution to the technological roadmap;*

INSERT YOUR TEXT HERE.

* + 1. Contribution to a global roadmap or programme

*Please give in-here the elements that demonstrate what are the important IPCEI-specific effective collaborations that the aid beneficiary has entered into with other IPCEI aid beneficiaries (so-called in previous IPCEI decisions “direct partners” – please replace with the actual term agreed and used by this IPCEI to refer to the aid beneficiaries) for delivery of their IPCEI individual projects and thus – of the objectives of the respective TF and its WSs, within and across WSs and across TFs.*

*Please note that each collaboration must be described in concrete terms and with sufficient details. The collaborations referred to should be: 1.) IPCEI-induced or IPCEI–enhanced, 2.) related to the scope and the objectives of the IPCEI, 3.) for individual R&D and FID projects (integrated into an IPCEI based on p.22-24 of the 2021 IPCEI Communication): “effective collaborations”. Their subject cannot be contractual research (performance of a research service or sub-contracting), neither simple supply/delivery relationships.*

INSERT YOUR TEXT HERE AND FILL OUT THE TABLE BELOW.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Related direct/associated participant | Organization type | Objective of cooperation | Subject and Scope of cooperation | Collaboration category |
| *Name (Member State)**WS/WP* | *LE, SME, Start-up* |  | *Relation with the individual project of the partner**Tasks, works, contributions of each collaborating partner* | *Demonstrate that the collaboration is IPCEI-induced or IPCEI-enhanced* |
| *…* | *…* |  | *…* | *…* |
| *…* | *…* |  | *…* | *…* |
| *…* | *…* |  | *…* | *…* |
| *…* | *…* |  | *…* | *…* |
| *…* | *…* |  | *…* | *…* |

Table 6: Cooperation with direct and associated participants

*Note: in annex to the portfolio, include evidence for the existence, the subject and the scope of such collaborations, as well as for the tasks of the collaboration partners must be provided (Letter of Intent, Memorandum of Understanding or some other appropriate document). In case the negotiations between the collaboration partners have not reached signing of binding collaboration agreement, please point out when the signature of the final binding collaboration agreement will be effected. In case of inability to provide a binding agreement at the stage of formal notification, please describe alternative means of effective delivery of the subject of the collaboration and its de-facto performance.*

*.*

1. Spill-over Effects

*Please describe in concrete terms what are the firm commitments decided to disseminate new knowledge and results of the IPCEI to the wider ecosystem, including for FID.*

* 1. Spill-over by non-protected results diffusion

*Publications and communication on individual IPCEI project’s generated knowledge results*

*For each KPI hereafter please explain the concrete commitment you’re taking (what communication publication, on which topic, in which cooperation, targeted to whom, on which event).*

*Refer to spill-over guidance.*

INSERT YOUR TEXT HERE AND FILL OUT THE TABLE BELOW.

|  |  |  |  |
| --- | --- | --- | --- |
| **Key performance indicator** | **Target without the IPCEI** | **Target with the IPCEI** | **Direct participant involved** |
| Scientific and industrial publication | A | B | =B-A |
| Papers and presentation |  |  |  |
| Collaboration with end users |  |  |  |
| Internal event workshop and seminars |  |  |  |
| Exhibition and conference |  |  |  |
| Organizer of external event |  |  |  |
| Funding of PhD student |  |  |  |
| Funding of Master thesis |  |  |  |
| Funding of University Chair |  |  |  |
| Training sessions |  |  |  |
| Other (TBP) |  |  |  |

*Table 7: KPI’s for the spill over on non-protected results*

* 1. Spill-over by IP protected results diffusion
		1. General Intellectual Property principles within the IPCEI

*IP management principles: In this section, the company has to describe how it handles IP management internally, i.e. on what is based the company’s IP strategy (e.g. protection of its technological assets by patents and/or trade secrets).*

*IP protection principles: The company has to describe how the key results of the project will be protected by the company (e.g. through patents, copyright or trade secrets or be disseminated with due care). The company should also identify its potential exploitable foreground IP. Moreover, the company should develop on rules to be agreed with the other partners concerning IP ownership, access rights to any background and foreground IP for the execution of the project, the side ground and the protection of IP and confidential information before the project starts. The company shall also indicate how the details of the management, sharing and exploitation of IP will be regulated in the partnership agreements to be established with partners.*

INSERT YOUR TEXT HERE.

* + 1. Dissemination by IP protected results diffusion

*Based on the principles detailed in section 4.2.1., the company must demonstrate here the flexibility of their usual principles:*

1. *In case of IP protected result it has to provide unconditional commitment to timely non-exclusive licensing of their R&D results at FRAND conditions to some interested parties in Europe (e.g. partners, customers, SMEs, ROs etc.);*
2. *In case of patent creation, point (a) equally applies. Explain the process the company will put in place to grant the licence (publication of the possibility to the targeted companies) and operational process of granting;*
3. *Describe situations where direct participants choose to establish a partnership or a joint venture for specific applications;*
4. *Describe situations where direct participants interact with academic institutions and RTOs for the use of the IP (e.g. in order to carry out research projects);*
5. *Describe situations where direct participants enter into confidentiality agreements with other users of the IP (e.g. with SMEs for testing prototypes);*
6. *Describe situations where the use of the IP protected results may lead to the development of standards.*

INSERT YOUR TEXT HERE.

* 1. Spill-over in FID phases

*Examples: Open infrastructures/capacity for SMEs, ROs, start-ups – commit to the exact capacity to be opened and to which entities. Commit also to other appropriate spill-overs for FID.*

*As with the IP protected results, we observe many different approaches amongst the individual projects as regards the nature of the dissemination activities and the level of commitment. We suggest that the Chapeau considers to elaborate on the following (indicative list):*

1. *Collaborations with SMEs, RTOs, start-ups and other indirect partners for knowhow exchange and other supporting activities in the development of a project idea, the validation of first results and the implementation of new solutions during the scaling-up of the project;*
2. *Standardisation activities for SMEs and start-ups;*
3. *Open infrastructure policy (access to SMEs, RTOs and start-ups, provision of pilot lines for R&D purposes, advocacy, research, touring, testing of prototypes etc.);*
4. *Collaborations with academic institutions for validation of results, provision of training, provision of research contracts etc.;*
5. *Collaborations with European OEMs, suppliers and customers and recycling companies (feedback loop and know-how sharing, testing, data gathering, sampling);*
6. *Procurement of materials and components and access to of laboratory capacities at market conditions.*

INSERT YOUR TEXT HERE.

* 1. Spill-over through collaboration with indirect participants

*Please describe the indirect participants, with whom the company has collaborations. Please describe how and why they were selected. For each collaboration with an indirect participant, please describe in concrete terms and with sufficient details:*

1. *Who is the collaborating partner, its type (SME, LE, RO)*
2. *What is the subject of this collaboration (IPCEI-related, IPCEI-induced or IPCEI-enhanced), how it relates to the your individual IPCEI project*
3. *What are tasks and works to be performed, and contributions of each collaborating partner*

*Please provide evidence for the existence of such collaborations, as requested in Chapter 3 (e.g. LOI, memorandum of understanding or some other appropriate document).*

*Please note,*

* *the collaboration relations to the indirect participants, included in this section, for individual R&D and FID projects (integrated into an IPCEI based on p.22-24 of the 2021 IPCEI Communication), must be an “effective collaboration” and cannot be contractual research (performance of a research service or sub-contracting), neither simple supply/delivery relationship.*
* *that the company does not need to duplicate the collaborations listed in this sub-section as spill-overs in the other spill-over sub-sections. Instead, please chose, according to your views on the main area of importance or contribution, in which particular spill-over sub-section such a collaboration (especially with research organisations), should be included.*

INSERT YOUR TEXT HERE AND FILL OUT THE TABLE BELOW.

|  |  |  |  |
| --- | --- | --- | --- |
| **Indirect participant** | **Type** | **Subject and scope of collaboration** | **Collaboration category** |
| *Name (Country)* | *LE, SME, Start-up, RO* | *Relation with the individual project of the partner**Tasks, works, contributions of each collaborating partner* | *Demonstrate how the collaboration is IPCEI-related, IPCEI-induced or IPCEI-enhanced* |
| *…* | *…* | *…* | *…* |
| *…* | *…* | *…* | *…* |
| *…* | *…* | *…* | *…* |
| *…* | *…* | *…* | *…* |
| *…* | *…* | *…* | *…* |

Table 8: collaborations with indirect participants of this IPCEI

1. Other positive effects on the market
	1. Increasing the level of R&D and innovations in Europe

*Description of how the project will increase the level of innovation and R&D in the sector and the European economy and society.*

INSERT YOUR TEXT HERE.

* 1. Impact of the Project on Employment and New Investments in Europe

*Estimation of the quantitative and qualitative impact of your project on direct and indirect employment and training in European economy and society new investments in Europe.*

*Detail the magnitude of employment that is envisioned*

* *Include a timeline of employment (how is employment associated with each step in the project?)*
* *Explain the nature of the employment? (Industry/qualifications of potential jobs)*
* *Explain whether the company will be training this extra workforce?*
* *Discuss the kind of indirect impact on employment there could be (employment that results from the project but not directly attributable to the company).*
* *Describe any downstream projects that could result in additional employment in the future? (either by the company or another firm)*

INSERT YOUR TEXT HERE.

* 1. Environmental protection and energy and security dependence

*Description of the project’s influence on environmental protection and reducing energy dependence.*

* *Describe how you plan to measure and report your company's* ***environmental performance as part of the project*** *(e.g., frequency and scope of publication, number and coherence of criteria included in the evaluation)*
* *Describe the measures you plan to adopt to move towards the* ***energy transition****, especially regarding process optimization, controlling dependence on fossil fuels or construction of zero carbon buildings (e.g. Amount of energy used (absolute value), source of energy used (in %): renewable or fossil, quantity of GHG produced)*
* *Describe the steps you plan to take to ensure* ***better water use*** *(e.g. use existing tools to measure the company's water footprint and identify strategic points for action, using a cost/benefit analysis of each water efficiency measure considered).*
* *Describe the steps you plan to take to ensure* ***better waste management*** *(e.g. integration of the ecodesign (upstream) and recycling (downstream) approach into the company's strategy, or systematic implementation of the recycling of the waste produced, if this is made possible by the material concerned).*

INSERT YOUR TEXT HERE.

* 1. Health data

*Describe the extent to which your project will allow the data to be used for research, therapeutic and industrial purposes in terms of (i) harvesting data, (ii) sharing data (storage and standardization) and (iii) insuring data security.*

INSERT YOUR TEXT HERE.

* 1. Market failures affecting the individual project

*Please expand on the market failures faced by your company in relation to your individual project, and explain how the project mitigates existing coordination problems that lead to market failure. Please focus on the concrete market failures that the project will face instead of describing general economic phenomena. Indicative list to be precised but not to be reducted.*

* + 1. Coordination challenges

*Explain in relation to your individual project if, why and how the ability to coordinate with other collaborating partners or to interact in order to deliver the R&D&I may be impaired for various reasons, including difficulties in coordinating due to the number of collaborating undertakings, intensity of collaboration, diverging interests among collaborating partners, problems in designing contracts, problems to coordinate collaboration.*

*Explain the difficulty due to the necessity to coordinate such a project with such divergent interests.*

* + - 1. Coordination failures between companies and research organizations

INSERT YOUR TEXT HERE.

* + - 1. Coordination failures between European research organizations themselves

INSERT YOUR TEXT HERE.

* + - 1. Coordination failures between SMEs and industry leaders

INSERT YOUR TEXT HERE.

* + - 1. Coordination failures between European clusters

INSERT YOUR TEXT HERE.

* + - 1. Coordination failures of a very large-scale R&D project

INSERT YOUR TEXT HERE.

* + - 1. Coordination failures associated with contractual incompleteness

INSERT YOUR TEXT HERE.

* 1. Imperfect and asymmetric information

*Explain the risks affecting the project, the difficulty to raise funding on the financial market or to obtain bank loans or guarantees and the difficulty to recruit.*

INSERT YOUR TEXT HERE.

* + 1. Risks affecting the project

*In addition to listing the risks that the project may encounter, please elaborate on how the company is planning to approach and minimize the risks.*

* + - 1. Technological risk

INSERT YOUR TEXT HERE.

* + - 1. Economic and financial risk

INSERT YOUR TEXT HERE.

* + - 1. Partnership risk

INSERT YOUR TEXT HERE.

* + - 1. Risk associated with major R&D programs

INSERT YOUR TEXT HERE.

* + - 1. Regulatory risk

INSERT YOUR TEXT HERE.

* + - 1. Strategic and organizational risk

INSERT YOUR TEXT HERE.

* + 1. Other market failures

*Describe, if any, other market failures specifically affecting the individual project (e.g. difficulty to recruit highly qualified personnel, strategic independence of supply, lack of incentive, negative externalities, high barrier to entry, absence of supply/incomplete market, unequal access to resources…).*

INSERT YOUR TEXT HERE.

* 1. Adequacy of the state aid instrument

*Explain whether the state aid instrument is in adequacy to correct the market failure:*

* *Grant = coordination default*
* *Financial instrument = Imperfect and asymmetric information*
* *Recoverable advance = risks taken in the project prior to marketing*
* *Adequacy compared to alternative funding schemes (e.g. Joint Undertakings/Horizon Europe)*
* *Adequacy compared to different State aid instruments*

INSERT YOUR TEXT HERE.

1. Incentive effect
	1. Absence of similar projects

*Explain that there is no similar project in Europe.*

INSERT YOUR TEXT HERE.

* 1. Start date of the project

*Explain that the project did not start before the aid application. Provide the dates of application and of start of works.*

INSERT YOUR TEXT HERE.

* 1. Counterfactual scenario

*Describe explicitly the effect of the state aid incentive effect on your company.*

*Describe what will happen when funding will not be realized for the project. If your company would not realize the project, how will your company maintain business capacity?*

*There should also be a counterfactual scenario at the overall IPCEI level, in order to understand what happens if the IPCEI would not take place. A counterfactual at IPCEI level could consist in technology developments taking place slower than with the aided IPCEI. That could be:*

* *A scenario without the project and a business as usual strategic roadmap that could be established with internal documentation*
* *An alternative internally approved scenario (that the evidence could be establish by internal documentation) => in that case the funding gap approach would be unappropriated (the state aid would not be superior to the difference between the counterfactual scenario and the scenario with state aid.*

*Description & substantiation of the counterfactual scenario at company level:*

* *The counterfactual scenario should be described in sufficient detail. E.g. a mere statement that "the company would not undertake the project as planned in its Member State without the aid" is not sufficient. It should be described in detail if it will not undertake the project at all, or will undertake it but in a different manner/extent, or will possibly undertake it somewhere else or undertake a different project. As the IPCEI Communication requires, the intended change must be specified (the change in behaviour which is expected to result from the State aid, that is to say whether a new project is triggered, or the size, scope or speed of a project is enhanced; The change of behaviour has to be identified by comparing what would be the expected outcome and level of intended activity with and without aid).*
* *This description can be in the technological field documents, or, if confidential in nature, in the accompanying company level text document.*
* *It is vital to have sufficient substantiation of the counterfactual,* eg.via *authentic internal company documents, showing that the company faces a clear choice and how the decision on whether to carry out the project is taken. This requirement is in line with the documentary evidence required in RDI State aid cases.*

*FGQ calculations:*

1. *In the absence of alternative project:*
* *If the counterfactual scenario is that there is no alternative project, there is no need for a counterfactual project tab with calculations in the Excel sheet. The Commission will only assess the eligible cost and funding gap calculations for the basic scenario.*
* *Proportionality of aid amount per beneficiary company: two step check of the IPCEI Communication in case there is no alternative project:*
1. *Identify the eligible costs: The possible eligible costs are listed in the Annex of the IPCEI Communication. The aid amount for any beneficiary can in no case exceed 100% of the eligible costs;*
2. *Identify the funding gap.*
* *In general, the aid amount corresponds to the funding gap. The aid amount can in no case exceed the eligible costs established in Step 1.*
1. *In case of a counterfactual alternative project:*
* *Where there is a counterfactual alternative project, there is a counterfactual tab in the Excel sheet with full calculation of the net present value of the positive and negative cash flows of the counterfactual project.*
* *Proportionality of aid amount per beneficiary company in the IPCEI Communication in case there is an alternative project:*

*Step 1) Identify the eligible costs in the basic scenario: The possible eligible costs are listed in the Annex of the IPCEI Communication. The aid amount for any beneficiary can in no case exceed 100% of the eligible costs;*

*Step 2) Identify the difference between the NPV of the alternative project and the NPV of the aided project in the basic scenario.*

* *In general, the aid amount corresponds to this difference. In the Excel sheet, it would be convenient to insert this calculation at the bottom of the basic scenario tab.*
* *The aid amount can in no case exceed the eligible costs established in step 1.*

INSERT YOUR TEXT HERE.

1. Elaboration on Terms of the Funding Gap Questionnaire
	1. Main hypothesis of the business plan

*Each aid beneficiary should provide all costs and revenues associated with the investment as a whole and the boundaries of investment should be defined from the perspective of the business investor: the calculation should include all (positive and negative) cash-flows for what the investor regards as the investment project, at the time these cash-flows are to be incurred. It is not enough to only submit the eligible costs. For the purpose of calculating the funding gap, what matters are all the costs (eligible or not) associated with the investment project and all the revenues over the entire lifetime including the mass production phase.*

* *The funding gap calculation is to be done consistent with the following methodology:*
* *For the purposes of this IPCEI, it is sufficient to provide the Excel sheet calculations for one scenario, the basic scenario (no optimistic and pessimistic scenarios and respective probabilities needed), provided the company is able to justify in the accompanying text document why this basic scenario is the most probable one.*
* *The funding gap that must be calculated is the funding gap of the investment project (i.e. all investment costs and operating costs) to be made by the company for the purpose of the IPCEI.*
* *The investments made for the IPCEI in R&D and FID by a company will generate revenues.*
* *The funding gap is the difference between discounted positive and negative cash flows over the entire economic lifetime of the investment project, i.e. covering the entire period during which the investments made generate revenues / the products that are produced thanks to programme. The investments are sold on the market. Hence, the funding gap must not be calculated only for the duration of the IPCEI project, which is up to the end of the FID phase, but must also cover the ensuing commercial/mass production phase.*
* *One option is to include in the excel sheet the best estimate projections that the company has for this entire period.*
* *Alternatively, companies could provide data for the explicit forecast horizon of the company and give a residual/terminal value (i.e. net present value of expected cash flow beyond the explicit forecast horizon for the remaining years of the economic lifetime), discounted to the current value. In that case, the number of years of mass production for which data are inserted should be realistic.*
* *Practically, in the Excel sheet, after the data for the FID phase and after the data for the reasonable number of years of mass production, a column should be inserted and contain the terminal value for the costs and for the revenues.*
* *Sales/revenues (positive cash flows): projected sales figures should be used by each company rather than a formula. These should be the figures actually used by the company in its business plan and decision making process. This can be best estimate figures. This data should overwrite the formula embedded in the Excel sheet which calculates sales/revenues as a function of costs, an assumption of idle share and an assumption of gross margin. Only if a company has no sales projections or any best estimate data, and only if it actually uses the formula embedded in the sheet (function of costs, idle share and gross margin) in its business plan and decision making process, should it apply the formula.*
* *Cash flows should normally be discounted using the weighted average cost of capital (WACC) of the company. The aid beneficiary should provide evidence that the discount factor applied is the actual WACC used by the company (e.g. by internal documents showing the applied WACC for investment analysis). The reason to deviate from the WACC usually applied by the company should be explained in detail.*
* *The end result of this step should be one figure: the amount of the funding gap, labelled as such in the Excel sheet.*

*(Hint: Sub-sections “Incentive effect” (7.2), including “Start date of the project”, “Increase in R&D and FID efforts” as well as “Risks affecting the project”, are inserted in other chapters of this project portfolio.)*

INSERT YOUR TEXT HERE.

* 1. Necessity of state aid

*Point 28 of the guidelines.*

*The aid must not subsidies the costs of a project that an undertaking would anyhow incur and must not compensate for the normal business risk of an economic activity. Without the aid the project’s realization should be impossible, or it should be realized in a smaller size or scope or in a different manner that would significantly restrict its expected benefits. Aid will only be considered proportionate if the same result could not be achieved with less aid.*

INSERT YOUR TEXT HERE.

* 1. Proportionality of state aid

*Point 30 of the guidelines*

*The funding gap and proportionality of aid will be assessed at the level of each clearly identifiable underlying individual component / single project.*

*The Proportionality of aid amount per beneficiary company in the IPCEI Communication is assessed by:*

1. *Identifying the eligible costs: The possible eligible costs are listed in the Annex of the IPCEI Communication. The aid amount for any beneficiary can in no case exceed 100% of the eligible costs;*
2. *Identifying the funding gap. The aid cannot be higher than the funding gap (and, at the same time cannot be more than 100% of eligible costs). The maximum aid amount corresponds to the funding gap, provided it does not exceed the eligible costs established in Step 1.*

INSERT YOUR TEXT HERE.

* + 1. Aid beneficiary’s hurdle rate

*According to point 32 of the IPCEI Communication: In the absence of an alternative project, the Commission will verify that the aid amount does not exceed the minimum necessary for the aided project to be sufficiently profitable, for example by making it possible to achieve an internal rate of return corresponding to the sector or firm specific benchmark or hurdle rate. Normal rates of return required by the beneficiaries in other investment projects of a similar kind, their cost of capital as a whole or returns commonly observed in the industry concerned may also be used for this purpose. All relevant expected costs and benefits over the lifetime of the project must be considered.*

INSERT YOUR TEXT HERE.

* + 1. Project’s funding gap

*Explain whereas the State aid (expressed in gross grant equivalent for non-transparent aid) is not exceeding the funding gap.*

INSERT YOUR TEXT HERE.

* + 1. Costs and state aid

INSERT YOUR TEXT HERE.

* + 1. State aid cumulation

INSERT YOUR TEXT HERE.

* + 1. Open selection proceeding

INSERT YOUR TEXT HERE.

* 1. Claw-Back Mechanism

*According to point 36 in the IPCEI Communication, a claw back mechanism will be applied during the IPCEI on Health. Please describe briefly how the company will provide e.g. according documents and proofs to fulfil the requirements within the defined claw back mechanism.*

INSERT YOUR TEXT HERE.

1. Limitation of distortion of competition and trade

*IPCEIs make it possible to bring together knowledge, expertise, financial resources and economic actors throughout the Union, so as to overcome important market or systemic failures and societal challenges which could not otherwise be addressed.*

*Please describe in this chapter in a detailed and comprehensive way why the IPCEI funding of your project will not lead to market, trade or competition distortion (or does so only to a very limited extent) and why in this context the development of your technology is necessary in Europe.*

* 1. Market affected by the State aid

*Describe the relevant market that could be worldwide in this sector and recent trends / evolutions (size, growth, competitors, market shares, barriers to entry, new entrants, mergers).*

* + 1. Current Industry Sector

*Description of the market situation (EU and worldwide) in this sector (market share, competitors).*

INSERT YOUR TEXT HERE.

* + 1. Estimation of the market situation

*Give details about the market situation (EU and worldwide) of the company before and after this project and compare it to the position of its main competitors on the relevant market. Describe briefly that market power is neither strengthened nor created.*

INSERT YOUR TEXT HERE.

* 1. Limiting distortion of dynamic incentives

*Please describe why the IPCEI funding will not deter your competitors’ investments in R&D and FID to develop competing technologies.* *No strengthening or creation of market power. Please explain why the IPCEI funding will not lead your company to market power (market leadership)*

INSERT YOUR TEXT HERE.

* 1. Failure to maintain an inefficient market structure

*Please describe why the technology you are addressing is not located in an “inefficient” market suffering from for example overcapacity nor a declining sector.*

INSERT YOUR TEXT HERE.

* 1. No effect on location activities

*Please describe that knowledge/technology that will be generated within the IPCEI will not be transferred to non-European locations of your company. Please describe that there will be no subsidy race within Europe.*

INSERT YOUR TEXT HERE.

1. Annex to the Portfolio
2. *Funding Gap Questionnaire*
3. *Internal Company Documents substantiating the counterfactual scenario*
4. *(If necessary) Documents related to the WACC calculation*
5. *Documents demonstrating the collaboration with direct, indirect, other participants*
1. Reference to (g) in the annex of the ICPEI communication from the Commission (2021/C(2021) 8481 final) [↑](#footnote-ref-1)